Business Wire

Bancor 3, The Ultimate DeFi Liquidity Solution, Goes Live With Launch Partners Polygon, Synthetix, Brave, Flexa, Yearn, Nexus Mutual & 30+ DAOs

11.5.2022 16:00:00 EEST | Business Wire | Press release

Share

Bancor (BNT), the inventor of DeFi and liquidity pools, has announced its new protocol version, Bancor 3, is now live. Bancor 3 is set to be the ultimate automated DeFi liquidity solution empowering token projects and their holders to drive healthy on-chain liquidity in their native tokens.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220506005455/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Bancor 3 (Graphic: Business Wire)

The launch has already attracted 30+ token projects and DAOs including Polygon (MATIC), Synthetix (SNX), Brave (BAT), Flexa (AMP), Yearn (YFI), Enjin (ENJ), WOO Network (WOO) and Nexus Mutual (wNXM), which are providing seed liquidity on the network or offering liquidity incentives via Bancor’s new customizable Auto-Compounding Rewards system.

Token projects and DAOs can use Bancor to:

  • Maintain liquid markets for their native token, facilitating cheaper token trading.
  • Enable token holders to earn safer, higher yields exclusively in their native token (Single-Sided Staking with 100% Impermanent Loss Protection).
  • Deploy Auto-Compounding Rewards that minimize sell pressure and are simultaneously used as fee-generating liquidity from day one.

Driving Sustainable Liquidity in DeFi

Decentralized liquidity is the backbone of DeFi, yet strategies employed by token projects to create long-term liquidity have proven ineffective. Due to the risk of negative returns from Impermanent Loss, most token holders today are reluctant to provide their tokens to liquidity pools. Meanwhile, liquidity mining rewards programs largely end up in the hands of “mercenary yield farmers” who hop from pool to pool liquidating earned rewards into their preferred asset, leaving the token projects high and dry.

Roughly two years after yield farming burst onto the scene and spawned the first “DeFi Summer” in 2020, DAOs and token communities are still searching for a safe, simple and sustainable way to drive decentralized liquidity.

Today, Bancor launches out of beta its new and improved third version, aimed at creating sustainable on-chain liquidity for token projects by giving participants access to Single-Sided Staking with no risk of Impermanent Loss, and providing them with Auto-Compounding and Dual Rewards. Liquidity providers are less likely to withdraw liquidity when rewards expire since they’re always protected from value loss and can earn with zero maintenance.

Bancor 3: The Ultimate DeFi Liquidity Solution

Bancor 3 introduces novel features that encourage broad and sustainable involvement in on-chain liquidity markets by dramatically simplifying passive liquidity provision in automated market-maker (AMM) liquidity pools. Key features include:

  • Omnipool: A new protocol architecture that consolidates token liquidity in a single, virtual vault, minimizing gas costs and increasing efficiency and usability at every touchpoint.
  • Unlimited Single-Sided Staking: Provide liquidity and earn yield in a single token; no need to pair 50/50 or buy another asset.
  • Auto-Compounding Earnings: Trading fees and rewards auto-compound with zero transaction fees, and are simultaneously used as liquidity inside the pool from day one. Auto-compounding is optimized via an integration with Chainlink Keepers.
  • Instant Protection: All deposited tokens receive 100% Impermanent Loss Protection instantly.
  • Single-Sided Pool Tokens: The first-ever fungible Single-Sided Pool Tokens. Unlike normal Pool Tokens, Single-Sided Pool Tokens only rise relative to their underlying assets, creating a new kind of “up only” money lego that is easily composable in other DeFi products.
  • Smart Portfolio: A new front-end interface gives full transparency into actual net earnings on deposited tokens.
  • Dual Rewards: Third-party token projects can now incentivize liquidity on Bancor with auto-compounding rewards free from Impermanent Loss.
  • Revamped Tokenomics: New BNT tokenomics create a more cost-efficient system for directing protocol liquidity to the highest-earning liquidity pools.

Mark Richardson, Product Architect at Bancor (BNT), said:

“Bancor has spent the past several years creating the equivalent of a high-yield savings account for DeFi: Deposit your assets, sit back and earn. By helping token projects and their users safely and simply tap into DeFi yields, Bancor 3 creates robust and resilient on-chain liquidity markets that drive healthy token economies.”

Hamzah Khan, Head of DeFi and Labs at Polygon (MATIC), said:

“Polygon is excited to utilize Bancor 3 to build decentralized liquidity for MATIC token holders. Bancor’s single-sided liquidity and impermanent loss protection mechanisms make it easier for our DAO and token holders to safely stake and earn MATIC, while driving community-sourced liquidity that powers low-slippage MATIC trading.”

Tyler Spalding, Co-founder of Flexa (AMP), said:

“Bancor has become one of the largest sources of on-chain AMP liquidity for a reason: It is a safe and simple way to stake. With Bancor 3, we’re doubling down on our belief in Bancor by providing auto-compounding rewards to our token holders who stake their AMP on Bancor.”

Useful links:

Bancor App

Bancor 3 Launch Details

About Bancor Protocol

Bancor is the only DeFi trading and staking protocol with Single-Sided Liquidity & 100% Impermanent Loss Protection. Overseen by the Bancor DAO, the protocol's mission is to bring DeFi mainstream by providing the simplest and safest way to trade tokens and earn passive income in DeFi.

Launched in 2017, Bancor was the first DeFi protocol. Today, it generates millions in fees per month for depositors, offering up to 30% APR on 150+ tokens like ETH, WBTC, LINK, MATIC, AMP, SNX & more. Bancor is the preferred treasury management solution of 30+ DAOs including Polygon, Nexus Mutual, UMA, KeeperDAO & WOO Network DAO.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nate Hindman
Nate@Bancor.Network

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye